Enhabit, Inc.

DB:X34 Stock Report

Market Cap: €351.1m

Enhabit Valuation

Is X34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of X34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: X34 (€6.85) is trading below our estimate of fair value (€17.51)

Significantly Below Fair Value: X34 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for X34?

Key metric: As X34 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for X34. This is calculated by dividing X34's market cap by their current revenue.
What is X34's PS Ratio?
PS Ratio0.3x
SalesUS$1.04b
Market CapUS$369.59m

Price to Sales Ratio vs Peers

How does X34's PS Ratio compare to its peers?

The above table shows the PS ratio for X34 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.9x
SYAB SYNLAB
1x4.4%€2.5b
V3V VITA 34
1x3.1%€73.9m
FME Fresenius Medical Care
0.6x3.8%€12.2b
M12 M1 Kliniken
0.9x8.2%€311.7m
X34 Enhabit
0.3x4.3%€369.6m

Price-To-Sales vs Peers: X34 is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (0.9x).

Price to Sales Ratio vs Industry

How does X34's PS Ratio compare vs other companies in the DE Healthcare Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
TLIK Arzneiwerk VIDA
0.08xn/aUS$4.76m
No more companies available in this PS range
X34 0.3xIndustry Avg. 0.6xNo. of Companies4PS00.40.81.21.62+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: X34 is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is X34's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

X34 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ratio1x

Price-To-Sales vs Fair Ratio: X34 is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst X34 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€6.10
€8.24
+35.2%
11.4%€10.02€7.29n/a5
Oct ’25€7.00
€8.34
+19.2%
10.9%€9.96€7.25n/a6
Sep ’25€7.45
€8.33
+11.8%
10.9%€9.95€7.24n/a6
Aug ’25€9.20
€8.58
-6.8%
14.3%€11.21€7.48n/a7
Jul ’25€8.05
€8.58
+6.5%
14.3%€11.21€7.48n/a7
Jun ’25€8.20
€8.65
+5.5%
13.2%€11.14€7.43n/a7
May ’25€9.50
€10.00
+5.3%
16.3%€12.82€7.78n/a7
Apr ’25€10.50
€10.00
-4.7%
16.3%€12.82€7.78n/a7
Mar ’25€8.15
€9.89
+21.4%
20.4%€13.76€7.34n/a7
Feb ’25€9.15
€9.89
+8.1%
20.4%€13.76€7.34n/a7
Jan ’25€9.40
€9.89
+5.3%
20.4%€13.76€7.34n/a7
Dec ’24€9.60
€9.45
-1.5%
23.2%€13.83€7.38n/a6
Nov ’24€6.85
€10.34
+51.0%
24.6%€14.21€6.63€6.106
Oct ’24€10.90
€10.53
-3.4%
24.3%€14.97€7.49€7.006
Sep ’24€11.60
€10.43
-10.1%
22.4%€14.70€7.35€7.457
Aug ’24€12.30
€12.05
-2.1%
22.1%€15.38€8.60€9.208
Jul ’24€10.80
€12.77
+18.3%
25.4%€18.33€8.71€8.058
Jun ’24€9.85
€13.62
+38.3%
21.1%€18.43€8.75€8.207
May ’24€11.00
€14.11
+28.3%
19.7%€18.13€9.97€9.507
Apr ’24€11.90
€15.07
+26.7%
17.4%€18.84€11.31€10.508
Mar ’24€14.20
€15.10
+6.3%
18.3%€18.70€11.22€8.157
Feb ’24€13.90
€14.77
+6.3%
16.3%€18.63€11.18€9.157
Jan ’24€12.10
€14.51
+19.9%
17.0%€18.72€11.23€9.406
Dec ’23n/a
€16.66
0%
15.9%€20.51€13.33€9.604
Nov ’23n/a
€17.46
0%
15.5%€20.25€13.16€6.854

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Ship Healthcare Holdings

JP¥196.5b

Engages in the medical, healthcare, welfare, and nursing care businesses worldwide.

5EZ

JP¥12.40

7D

-3.1%

1Y

-4.6%

Sensus Healthcare

US$125.2m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

5TX

US$7.25

7D

16.0%

1Y

272.6%

CVS Health

US$66.9b

Provides health solutions in the United States.

CVS

US$53.25

7D

2.4%

1Y

-14.7%